Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
October 23, 2014Celator Pharmaceuticals prices an underwritten public offering of 6,611,150 shares of common stock. The proceeds are expected to be $12.9 M and they intend to use the net profit for clinical trial, R&D, manufacturing and potential acquisition expenses.
More »
aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research
October 22, 2014John C. McKew, Ph.D., joined aTyr Pharma as Vice President, Research. With more than two decades of expertise in rare disease research, he will lead aTyr's efforts to expand and translate its novel therapeutic model to treat rare diseases.
More »
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
October 22, 2014Atara doses the first patient in its Phase 1 clinical study to assess the safety, tolerability and efficacy of STM 434, an Activin inhibitor, in treating ovarian cancer and other solid tumors independently and in combination with liposomal doxorubicin.
More »